{"id":"W2635951006","doi":"10.1056/nejmoa1613493","title":"First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer","year":2017,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2575,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Nivolumab; Docetaxel; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Lung; Cancer; Stage (stratigraphy); Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001449795,0.0004073133,0.001436677,0.0002291938,0.0002046282,0.0004363937,0.0005985444,0.0006273591,0.001528847],"category_scores_gemma":[0.001782789,0.0002092553,0.0008589214,0.0001747616,0.0003555901,0.0003124627,0.0002305892,0.00120841,0.0002130705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001190644,"about_ca_system_score_gemma":0.000988376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008944154,"about_ca_topic_score_gemma":0.003245738,"domain_scores_codex":[0.9995322,0.0002340248,0.00003063403,0.00007181174,0.00006169765,0.0000696502],"domain_scores_gemma":[0.9991853,0.0002629652,0.0001558849,0.00004902107,0.00004998944,0.0002967532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5343983,0.01406265,0.0514078,0.00237654,0.002163161,0.000338076,0.0003410515,0.00512767,0.02168603,0.0002896049,0.003591515,0.3642175],"study_design_scores_gemma":[0.277343,0.4946924,0.1892891,0.0004428255,0.002817696,0.001917552,0.0002380248,0.007268304,0.01518739,0.0008095567,0.009914649,0.00007948939],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929263,0.005713487,0.0001426545,0.0001734318,0.0001210207,0.0002148817,0.00007509616,0.0000217678,0.000611358],"genre_scores_gemma":[0.9975612,0.001421773,0.0002392881,0.0001639113,0.00006945395,0.0001193295,0.0001376692,0.000004777601,0.0002825152],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001528847,"threshold_uncertainty_score":0.008638799,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03511857503314067,"score_gpt":0.3199291267709563,"score_spread":0.2848105517378156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}